Skip to main content
OpenTrials

Clinical trial condition

Meningococcal Infections

Explore clinical trials studying Meningococcal Infections. Study availability and eligibility vary by location and protocol.

216 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Meningococcal Infections trial results

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

NCT00463437

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +38 more
Locations
  • GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bönnigheim, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bretten, Baden-Wurttemberg, Germany
  • GSK Investigational Site Ettenheim, Baden-Wurttemberg, Germany
View all 63 locations
View Trial Details
Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

NCT02986854

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Anaheim, California, United States
View all 37 locations
View Trial Details
Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

NCT00474266

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Jarvenpaa, Finland
View all 14 locations
View Trial Details
Completed

Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

NCT00674583

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Draguignan, France
  • GSK Investigational Site Laon, France
  • GSK Investigational Site Le Havre, France
  • GSK Investigational Site Lingolsheim, France
View all 31 locations
View Trial Details
Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

NCT01934140

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Research Institute for Tropical Medicine Muntinlupa City, National Capital Region, Philippines
  • Philippine General Hospital Manila, Philippines
View Trial Details
Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

NCT02946385

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Jarvenpaa, Finland
View all 17 locations
View Trial Details

Related conditions